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ABSTRACT 
The concept of local drug delivery in the form of microspheres has potential for use as an alternative to conventional therapy strategies in the 
treatment of pain and inflammatory symptoms in case of certain bone and joint diseases. Commonly preferred treatment options for these 
symptoms (such as oral NSAIDs, analgesics, opioid pain medications) need to be frequently administered or applied and additio nally, these 
suffer from multiple limitations. A prolonged release formulation of an NSAID i.e. Diclofenac Sodium, might prevent frequent administrations 
and improve the therapeutic outcome. In the current research, Diclofenac Sodium (DS)-loaded microspheres were prepared using thermal 
control and ionic cross-linking techniques. Calcium sulfate hemihydrate (CaSO4·0.5H2O) was used in specific quantities to enhance the self-
hardening property of the microspheres. An encapsulation efficiency and loading capacity of up to 90.24% and 61.41% respectively were 
achieved from the formulations. FTIR analysis indicated no major interactions between the active ingredient and the excipients used in the 
formulation process. In-vitro studies on the biodegradability of the microspheres disclosed that the microspheres showed a slow degradation 
pattern over time. Release study of the prepared microspheres revealed that the release of DS was prolonged achieving release of drug over a 
period of up to 11 days. The microspheres seem to fulfill the requisite criteria in-vitro. The results obtained suggest that DS-loaded 
microspheres have the potential for further investigation and development. 
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INTRODUCTION 
Joint pain and inflammation are the major symptoms of bone 
and joint diseases and are important considerations in the 
treatment of these diseases.1 Such diseases that directly or 
indirectly lead to these symptoms include but not limited to- 
Osteoarthritis, Rheumatoid arthritis, Osteoporosis, Paget’s 
disease. The symptoms of these disease can involve 
functional restrictions but pain and inflammation in the bone 
joints are the most common and as such the clinical 
management of these diseases is mostly focused on pain 
relief and management.2 However, the conventional 
treatment strategies commonly adopted for these situations 
suffer from a several limitations comparable to non-
specificity of drug release which directly leads to limitations 
in their clinical utility, potential side effects of drugs due to 
requirement of larger doses to elicit a desired therapeutic 
response as well as fluctuations in drug concentrations 
which can either lead to good or bad therapeutic response 
depending upon whether the Cpss values fall or rise in the 
therapeutic range. 
Current treatment approaches for treating joint pain and 
inflammations include oral administration of analgesics 
(acetaminophen), opioid pain medication (tramadol), non-
steroidal anti-inflammatory drugs (naproxen, ibuprofen, 
diclofenac sodium) as well as tricyclic anti-depressants that 
have been found to be moderately effective in back pain and 
rheumatoid arthritis.3,4 Topical application of NSAIDs has 
also proven helpful in some cases.5 Invasive procedures 
include injections of corticosteroids or hyaluronic acid.6 
Non-steroidal anti-inflammatory drugs (NSAIDs) are one of 
the most commonly used drugs to ease the pain, 
inflammation and stiffness that come with arthritis, bursitis 
and tendinitis.7 Most NSAIDs are cheap and often among the 
first medicines prescribed for people with achy joints.  They 
are available to take by mouth or to rub on the skin over 
painful joints and muscles. 
These therapeutic approaches have mainly focused on 
systemic/conventional administration of drugs. This results 
in poor bioavailability and biodistribution, prolonged 
therapy process, frequent intake of drug and low efficacy of 
the therapy as well as poor retention time at the diseased 
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site. Moreover, blood perfusion to the bone is less as 
compared to other organs in the body. Additionally, drugs 
injected at the diseased sites by intra-articular approaches 
are often cleared from the site very rapidly (t1/2 ∼0.1–6 h).8,9 
Topical delivery of drugs has its own set of limitations.10 To 
treat the diseases effectively, improvised methods are 
required, ideally keeping the drug concentrations high at 
specific sites on the skeletal system without high systemic 
levels. Buchholz et al., in the 1970s, recognized local drug 
delivery to the bone as a potential approach to treat bone 
diseases and conceptualized the skeletal drug delivery 
system.11 
Though the development of active targeting delivery systems 
greatly enhanced the drug concentration at desired disease 
site after systemic administration, it is still a challenge to 
control the drug distribution in other organs, especially the 
high accumulation of nanoparticles in liver or spleen. Local 
delivery from a drug depot could be a viable alternative. 
They are especially suitable for the treatment of osteoporotic 
fractures.12 One of the most investigated and attractive 
prospects for delivery of pain medications to the diseased 
joints is microspheric drug delivery system. This delivery 
system offers certain advantages over conventional methods 
of treatment of joint pain and inflammation and also 
overcomes some of their limitations. Microspheres permit 
intimate and prolonged contact with the diseased site which 
has the potential to maximize both the rate as well as the 
extent of drug absorption. They protect the drug from the 
degradative environment and enzymes inside the body, 
reduce frequency of drug intake, reduce side effects, improve 
bioavailability, reduce fluctuations in plasma drug 
concentrations, and promote controlled release of the 
medication.13 
Ethyl cellulose (EC) and Sodium Carboxymethyl cellulose 
(Na-CMC) have been studied as one of the materials for 
controlled release of NSAIDs.14,15 
In the current investigation, formulation of DS releasing 
polymeric microspheres of Ethyl cellulose (EC) and Sodium 
Carboxymethyl cellulose (Na-CMC) was attempted. The DS-
loaded EC and Na-CMC microspheres were prepared by 
thermal control and ionic cross-linking techniques with 
varying polymer quantities and with the incorporation of 
specific quantities of (CaSO4). Several properties of the 
prepared microspheres were studied by suitable evaluation 
parameters namely drug encapsulation efficiency and 
loading capacity, yield, particle size analysis, micromeritic 
properties, moisture loss, buoyancy, compatibility studies by 
FTIR Analysis, surface morphology by SEM Analysis, in-vitro 
biodegradability and drug release pattern. 
MATERIALS AND METHODS 
Materials: Diclofenac Sodium was procured from Central 
Drug House (P) Ltd., New Delhi. Ethyl Cellulose and Sodium 
Carboxymethylcellulose were obtained from SDFCL, Mumbai. 
Cyclohexane and Sodium Alginate were acquired from 
Universal Laboratories Pvt. Ltd., Mumbai and Loba Chemie 
Pvt. Ltd. respectively. n-Hexane and Calcium chloride were 
obtained from SDFCL, Mumbai. All chemicals used in the 
research are of analytical grade and were used as received. 
Methods: 
Solubility testing of drug: This study was performed by 
taking an excess quantity of drug sample in specified 
quantities of different solvents- water, ethanol, methanol, 
acetone, PBS pH 7.4 and cyclohexane.16,17 
Melting point of drug: This study was carried out by Thiele 
tube method to indicate the purity of the sample. Adequate 
quantity of drug was filled in a glass capillary tube and the 
tube was attached to a thermometer by using a string or 
rubber band. The thermometer was dipped in fresh mineral 
oil placed inside the Thiele tube. From the bottom, heat was 
applied by means of a Bunsen burner and the temperature at 
which the drug melts is noted.18,19 
Drug identification by FTIR Analysis: FTIR spectra of 
sample drug was recorded and the obtained peaks in the 
fingerprint region were compared with that of Diclofenac 
Sodium reference standard (B.P.) to confirm whether the 
taken sample is Diclofenac sodium. 
Preparation of Phosphate buffer saline (pH 7.4): PBS pH 
7.4 was chosen as the solvent medium to prepare the 
calibration curve of the drug as well as act as the release 
medium for drug release studies from the formulations as 
the pH of the synovial fluid has been measured to be ~7-
7.5.20,21 NaCl (8gm), KCl (0.2gm), Na2HPO4 (1.44gm) and 
KH2PO4 (0.24gm) were accurately weighed and mixed 
thoroughly until solubilization in 1000mL distilled water 
contained in a 1000mL volumetric flask. 
Preparation of Standard Curve of Diclofenac Sodium: 
100mg of sample drug was taken in 100mL volumetric flask. 
Then, make up the volume to 100mL with 100mL PBS. This 
was marked as 1st stock. From the 1st stock, 10mL was 
taken and made up to 100mL with PBS. This was marked as 
2nd stock. From the 2nd stock, 1, 2, 3, 4, 5, 6 and 7 mL were 
taken in separate volumetric flasks and made up to 10mL 
each with PBS to get concentrations- 10, 20, 30, 40, 50, 60, 70 
µg/mL respectively. Absorbance of each was checked in UV 
Spectrophotometer and graph was plotted. 
Wavelength selection: Accurately weighed 100mg of drug 
(Diclofenac Sodium) was dissolved in 100mL of Phosphate 
buffer pH 7.4. After necessary dilutions, the resulting 
solution was scanned in the 190-400nm UV region to obtain 
the wavelength maxima. This wavelength was chosen for 
further analysis. 
Preparation of DS-loaded microspheres: The required 
formulations i.e. microspheres were prepared by two 
separate methods i.e. Thermal control and Ionotropic cross-
linking. 
Thermal control technique- DS-loaded EC microspheres 
were prepared using thermal control method at mass ratios 
of 1:1, 1:1.5 and 1:2 (DS:EC+CaSO4). The method of 
preparation was developed with modifications from the 
technique used by Jalsenjak et.al. (1976).22 50mL 
cyclohexane was taken in a beaker which was placed over a 
magnetic stirrer at 400 RPM and temperature set at 50ºC. 
Specific quantity of the coating material, Ethyl cellulose, was 
added to the beaker and temperature was gradually 
increased to 70º and maintained for about 25-30 minutes. 
The core material to be encapsulated, Diclofenac Sodium, 
was then added to the beaker and temperature was further 
increased to 80ºC. After maintaining the same conditions for 
another 60 minutes, the system was allowed to cool down to 
room temperature along with continued stirring. The 
microspheres were collected by filtration and washed with 
n-hexane three times. The microspheres were dried in a hot 
air oven at 40ºC for a period of 4 hours and stored. 
Incorporation of CaSO4 hemihydrate (12.5%, 25%, 50% and 
75% of total polymer quantity) was carried out in certain 
formulations to obtain self-hardening microspheres. CaSO4 
was added at the same time polymer was added to the 
solvent system during formulation. 
Formulations F-1 through F-15 were prepared by this 
technique. 
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Ionotropic cross-linking method- DS-loaded NaCMC 
microspheres were prepared by ionotropic cross-linking 
method with mass ratios of 1:1 (DS:NaCMC) and 1:1 
(DS:NaCMC+CaSO4). Under this technique of preparation of 
microspheres, there occurs a cross-linking of 
polyelectrolytes in the presence of counter-ions in the 
solution. This results in the formation of microspheres.23,24 2-
3% Sodium alginate solution was prepared in a beaker and 
heated gently along with stirring. Suitable amounts of 
polymer (Na-CMC), drug and CaSO4 were added to the above 
solution. The resulting mixture was injected through a 24 
gauge syringe into 10% CaCl2 solution. Microspheres were 
collected on a filter paper, were washed with distilled water 
two to three times and dried in a hot air oven at 40ºC for 4 
hours. Formulations F-16 and F-17 were prepared by this 
method. 
Characterization of the prepared microspheres: 
Determination of Drug Encapsulation Efficiency and 
Loading Capacity-25,26 
Accurately weighed 100mg of microspheres were suspended 
in 10ml PBS. The suspension was sonicated for 2-3 minutes 
and microspheres were isolated by filtration through 
Whatman filter paper. The filtrate was analysed for drug 
content after suitable dilution which indicated the free 
untrapped drug. 
Encapsulation efficiency % = 
                                    
                
       
Loading Capacity % = 
                    
                          
       
Determination of Percentage Yield-27 
% yield of microspheres was calculated by dividing total 
weight of the formulation by the total weight of non-volatile 
excipients used in the preparation of the formulation and is 
expressed as: 
Yield % = 
                           
                         
       
Particle size analysis- 
Particle size of the prepared microspheres was determined 
by optical microscopy method. The size of microspheres was 
measured by a calibrated ocular and stage micrometer. 100 
microspheres from one formulation of each batch 
(containing 0%, 12.5%, 25%, 50% and 75% CaSO4) were 
taken at random and analyzed for their size and particle size 
distribution was plotted.28 
Loss of Moisture- DS-loaded microspheres with varying 
quantities of polymers and ingredients were subjected to 
moisture loss studies which provide an insight on the 
hydrophilic nature of the microspheres. 500mg of prepared 
microspheres were weighed accurately and then stored in a 
desiccator at 37ºC for 48 hours containing fused calcium 
chloride which is hygroscopic in nature and as such has the 
tendency to readily absorb moisture from the surroundings. 
Final weight was noted when no further change in weight of 
sample was observed.29 
Moisture loss %= 
                         
             
       
Micromeritic properties- 
The prepared formulations were also evaluated for their 
micromeritic properties such as- Angle of Repose, bulk 
density, tapped density, Carr’s index and Hausner’s ratio. 
Angle of repose- It can be defined as the steepest angle at 
which a sloping surface formed of loose material is stable. It 
is indicative of inter-particular and cohesive forces as well as 
the flow properties of the material being investigated. Angle 
of repose of the formulated microspheres was measured by 
the fixed funnel method. The microspheres were poured 
through the funnel onto a stable base such that a heap of 
particular height and diameter is formed.30 The angle of 
repose was determined by measuring the height and 
diameter of the heap of powder and calculated from the 
equation- 
Angle of Repose, θ = tan-1 
      
      
  
The obtained angle is then compared and checked against 
the Carr classification of flowability of powder based on 
repose angle to understand the flow properties of the 
microspheres-31 
Bulk and tapped density- Bulk and tapped density of 
formulation was found out using a 10ml graduated cylinder. 
Formulation was poured into the cylinder and the volume 
occupied was noted. Then, the cylinder containing the 
sample was tapped 100 times using the bulk density 
apparatus and the final volume was noted. Bulk and tapped 
density were calculated using the formula-32 
Bulk density = 
              
                              
 
Tapped density = 
              
                             
 
Carr’s index- also called compressibility index, it was 
calculated by the following formula. 
Carr’s index = (
                           
              
)      
Hausner’s ratio- Hausner’s ratio of formulations was 
calculated by comparing the tapped density with bulk 
density using the equation. 
Hausner’s ratio = 
              
            
 
The calculated Carr’s index and Hausner’s ratio are then 
compared and checked against the standard values. 
In-vitro Buoyancy study- This test is done to check the 
floating properties of the formulated microspheres. 
Microspheres are spread over the surface of the release 
medium and are allowed to float at the surface or settle 
down to the bottom during a specific time period under 
constant agitation. At the end of the test period, the floating 
and settled microspheres are recovered separately, dried 
and weighed.33 
Buoyancy % = (
                              
                                      
)      
FTIR Spectrophotometric analysis- 
The FTIR spectra of pure drug, drug with polymers (Ethyl 
cellulose, Sodium Carboxymethyl cellulose) and prepared 
formulations were recorded to study compatibility and any 
possible interactions between the drug and other excipients. 
Surface morphology- 
The surface characteristics of the microspheres were 
observed by SEM. 
In-vitro biodegradability studies- 
This test was carried out to gather knowledge of the 
degradation pattern of the formulated microspheres. 500mg 
microspheres were added to a sufficient quantity of PBS and 
placed in an incubator at 37ºC. Every three days collect the 
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microspheres by filtration and dry them completely by 
placing them in a hot air oven at 40º-45ºC for 3-4 hours. 
Weigh the dried microspheres. The differences in weight was 
checked by comparing it to the previously noted weight. 
After weighing place the microspheres in fresh PBS buffer 
and repeat the process every three days.34 
In-vitro Drug release studies- 
Formulations were analysed for their drug release properties 
by taking 100mg drug equivalent weight of formulation in a 
15mL centrifuge tube and adding 10mL pH 7.4 phosphate 
buffer. The centrifuge tube was placed in an incubator with 
temperature conditions set at 37º±2ºC. 7mL samples were 
taken at regular intervals (3, 24, 48, 72, 96 hours and so on) 
and same amount of fresh buffer was introduced to maintain 
sink conditions. The withdrawn samples were suitably 
diluted and analysed by UV Spectrophotometer. 
Kinetic modelling of drug release- 
The drug release kinetics were studied using various models 
such as zero-order, first-order, Higuchi, Korsmeyer-Peppas 
and Hixon-Crowell. To study the release kinetics, data 
obtained from in-vitro drug release studies were plotted in 
the models. The best fit model was confirmed by the value of 
correlation coefficient near to 1. If n value is 0.45 or less, the 
release mechanism follows “Fickian diffusion” and higher 
values of 0.45 to 0.89 for mass transfer follow a non-fickian 
model (anomalous transport). The drug release follows 
Higuchi model of drug release and case II transport if the n 
value is 0.89. For the values of n higher than 0.89, the 
mechanism of drug release is regarded as super case II 
transport. 
RESULTS AND DISCUSSION 
Solubility studies of drug-It was carried out to test 
solubility of the drug in different solvents as well as to test its 
solubility in the dissolution medium (PBS pH 7.4) to be used. 
10mL solvent was taken in a test tube and to it an excess 
amount of drug sample was added. The test tube was 
subjected to slight agitation and the solubility was checked. 
Sample of Diclofenac sodium taken was found to be highly 
soluble in methanol and acetone, freely soluble in ethanol 
and sparingly soluble in water, PBS buffer and cyclohexane. 
Melting point of drug- After performing the melting point 
study using Thiele tube method, the melting point of the 
sample drug was noted to be 286.5ºC. 
Drug identification- 
 
 
Fig 1: FTIR Spectra of sample drug 
 
Fig 2: FTIR Spectra of Diclofenac Sodium reference standard (British Pharmacopoeia) 
Comparing the fingerprint region of Diclofenac RS (British Pharmacopoeia) with that of the sample showed that the peaks 
obtained are similar. Hence, the sample used was identified to be Diclofenac Sodium. 
Standard curve of Drug: 
 
Fig 3: Standard curve of Diclofenac Sodium in pH 7.4 phosphate buffer 
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Standard curve for Diclofenac Sodium shows linearity over 
the range of 10-70µg/mL with regression equation 
y=0.0263x-0.0077 and correlation co-efficient R2 value 
found to be 0.9989. On the basis of the regression equation, 
concentration of drug in various samples were calculated 
during the drug release studies. 
Wavelength selection: The wavelength maxima (λmax) was 
observed at 276nm and this wavelength was adopted for 
further absorbance measurement. 
Preparation of DS-loaded microspheres: The two 
methods adopted for preparation of microspheres i.e. 
thermal control and ionotropic cross-linking were found to 
be good as indicated by the high yield of microspheres in F-1 
through F-17. Higher yield was indicative of lesser wastage 
and high efficiency of the encapsulation process. Ethyl 
cellulose and Sodium Carboxymethyl cellulose were used as 
polymers in varying ratios to prepare different batches of 
microspheres. CaSO4 hemihydrate was used as an additional 
excipient to enhance the hardening of the microspheres. In 
thermal control technique, temperature was varied from 
50ºC to 80ºC during different steps in the process to 
facilitate solubilisation of the polymer in the solvent as well 
as promote encapsulation of drug by the polymer. The 
prepared formulations were washed adequately with n-
hexane to remove any traces of cyclohexane. Ionotropic 
cross-linking method was used to prepare two successful 
microsphere formulations (F-16 and F-17). Stirring rate and 
height of injection were varied to obtain smaller particle size 
of formulation. 
The ingredients used for the preparation of microspheres 
and their respective quantities are depicted in Table 1 
. 
Table 1: Formulation ingredients and respective quantities used for the preparation of microspheres 
 
 
Characterization of the prepared microspheres: 
Determination of drug encapsulation efficiency and 
loading capacity- 
Phosphate buffer pH 7.4 was used as the solvent to 
determine the drug encapsulation efficiency and drug 
loading capacity of the formulated microspheres. 
Encapsulation efficiency of the microspheres ranged from 
67.88% to 90.24% with F-13 showing the lowest and F-5 
showing the highest encapsulation. Encapsulation efficiency 
of the formulations were found to be high which might be 
due to the lesser solubility of the drug in cyclohexane and 
PBS. Drug loading capacity ranged from 22.94% to 61.41% 
as shown in Table 2. It was observed from the experiment 
that as the concentration of CaSO4 in formulation is 
increased its encapsulation efficiency is reduced i.e. higher 
concentration of CaSO4 results in lesser amount of drug 
being encapsulated and more amount of drug wastage 
during the encapsulation process. This could be the possible 
reason for loss of 10-30% of drug during the encapsulation 
process. Another explanation for loss of drug could be the 
presence of drug molecules on the surface of the formulated 
microspheres which when washed leads to drug removal 
leading to reduced % encapsulation in the microspheres. 
Drug encapsulation efficiencies and loading capacities of the 
various formulations are given in Table 2. 
Determination of percentage yield- 
It was noted that the % yield for all the formulations was 
well over 50% which indicated the suitability of the methods 
used for the preparation of microspheres. Yield of 
microspheres ranged from 70.1% to 99.8% as demonstrated 
in Table 2. Determination of yield of each formulation was 
performed in a triplicate manner. These results also indicate 
that there was minimal loss of ingredients during the 
formulation process. It was also observed that whilst in 
some batches the % yield of microspheres increased with 
increase in polymer concentration, in others yield decreased 
with increase in polymer concentration. This variation can 
be attributed to the varying quantities of CaSO4 used during 
the formulation of different batches. 
 
 
 
Formulation Diclofenac Sodium Ethyl Cellulose Sodium CMC Calcium Sulfate Cyclohexane Sodium Alginate CaCl2
F-1 500mg 500mg - - 50mL - -
F-2 500mg 750mg - - 50mL - -
F-3 500mg 1000mg - - 50mL - -
F-4 500mg 437.5mg - 62.5mg 50mL - -
F-5 500mg 656.25mg - 93.75mg 50mL - -
F-6 500mg 875mg - 125mg 50mL - -
F-7 500mg 375mg - 125mg 50mL - -
F-8 500mg 562.5mg - 187.5mg 50mL - -
F-9 500mg 750mg - 250mg 50mL - -
F-10 500mg 250mg - 250mg 50mL - -
F-11 500mg 375mg - 375mg 50mL - -
F-12 500mg 500mg - 500mg 50mL - -
F-13 500mg 125mg - 375mg 50mL - -
F-14 500mg 187.5mg - 562.5mg 50mL - -
F-15 500mg 250mg - 750mg 50mL - -
F-16 500mg - 500mg - - 1.125gm 10gm
F-17 500mg - 437.5mg 62.5mg - 1.125gm 10gm
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Table 2: Drug encapsulation efficiency, Loading capacity and % Yield of the formulations 
 
 
Particle size analysis- 
Several formulation conditions such as- drug:polymer ratio, 
volume of the internal and external phase, stirring speed, 
height of injection etc. can be exploited to obtain 
microspheres of desired size range. According to a study by 
Saravanan et.al. (2011), smaller sized microspheres tend to 
get rapidly cleared from the joints after intra-articular 
administration. Additionally, larger microspheres show 
better sustained release properties than smaller 
microspheres due to the difference in surface area.35 It has 
also been reported that larger sized particles have better 
retention properties.8 
The average size of DS-loaded microspheres containing 0% 
(F-3), 12.5% (F-6), 25% (F-9), 50% (F-12), 75% (F-15) and 
F-17 were measured to be 50.52µm, 53.18µm, 55.71µm, 
57.22µm, 56.49µm and 62.74µm respectively. 
 
 
Fig 4: Particle size distribution of F-3, F-6, F-9, F-12, F-15, F-17 
Loss of Moisture- 
This evaluation of the prepared formulations was carried out 
under the specified conditions mentioned previously. After 
performance of the test and necessary calculations, it was 
noted that very small amounts of moisture were lost from 
the formulations which imply that the prepared 
microspheres contained negligible quantities of moisture. 
Moisture loss % was highest for F-13 i.e. 5.8% and lowest for 
F-6 and F-10 i.e. 1.2%. The results of moisture loss studies 
are given in Table 3 
. 
 
 
 
Formulation EE% DL% Yield %
F-1 86.09 61.41 70.1
F-2 88.03 45.09 78.08
F-3 87.38 40.87 71.26
F-4 85.6 42.46 92.71
F-5 90.24 36.47 98.96
F-6 85.79 29.82 95.86
F-7 83.96 41.98 85.28
F-8 85.15 37.67 90.4
F-9 81.91 27.34 99.86
F-10 74.57 41.52 89.8
F-11 77.12 33.67 91.6
F-12 79.86 27.57 96.53
F-13 67.88 36.69 92.5
F-14 70.27 37.26 75.44
F-15 72.25 31.52 76.4
F-16 87.77 25.34 81.5
F-17 85.14 22.94 87.34
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Table 3: % moisture loss from the formulations 
 
 
 
Fig 5: % moisture loss from the formulations 
Micromeritic properties- 
Table 4: Results of micromeritic properties analysis of the prepared microspheres 
 
Formulation Initial Weight Final Weight % moisture loss
F-1 500 482 3.6
F-2 500 474 5.2
F-3 500 487 2.6
F-4 500 481 3.8
F-5 500 485 3
F-6 500 494 1.2
F-7 500 487 2.6
F-8 500 493 1.4
F-9 500 484 3.2
F-10 500 494 1.2
F-11 500 488 2.4
F-12 500 482 3.6
F-13 500 471 5.8
F-14 500 476 4.8
F-15 500 487 2.6
F-16 500 485 3
F-17 500 492 1.6
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Formulation Bulk Density Tapped density Carr's index Hausner's ratio Angle of repose Flow Properties
F-1 0.333 0.378 11.9 1.13 34.99 Good
F-2 0.375 0.465 19.35 1.24 41.63 Fair
F-3 0.411 0.475 13.47 1.15 36.86 Good
F-4 0.427 0.473 9.72 1.1 25.55 Excellent
F-5 0.485 0.521 6.9 1.07 27.47 Excellent
F-6 0.533 0.575 7.3 1.08 26.56 Excellent
F-7 0.4 0.454 11.89 1.13 37.3 Good
F-8 0.434 0.48 9.58 1.11 20.55 Excellent
F-9 0.447 0.499 10.42 1.12 36.38 Good
F-10 0.39 0.472 17.37 1.21 43.36 Fair
F-11 0.424 0.467 9.21 1.1 24.62 Excellent
F-12 0.462 0.508 9.05 1.1 23.19 Excellent
F-13 0.362 0.411 11.92 1.14 36.38 Good
F-14 0.355 0.38 6.57 1.07 29.05 Excellent
F-15 0.449 0.509 11.78 1.13 37.87 Good
F-16 0.517 0.559 7.51 1.08 24.77 Excellent
F-17 0.482 0.545 11.55 1.131 36.47 Good
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The results of micromeritic properties of the formulations 
are shown in Table 4. Bulk density of the various 
formulations ranged from 0.333 to 0.533gm/cm3 while 
tapped density ranged from 0.378 to 0.575gm/cm3. These 
values were satisfactory and indicated good packability of 
the formulations. From the calculations of bulk and tapped 
density, Carr’s index and Hausner’s ratio were derived which 
ranged from 6.57% to 19.35% and from 1.07 to 1.24 
respectively. Formulation F-14 showed best compressibility 
property with a Carr’s index of 6.57. Angle of repose of the 
formulations ranged from 20.55º-43.36º. All the 
formulations showed satisfactory micromeritic properties 
which indicated their good flow characteristics. 
In-vitro Buoyancy study- 
The floating behaviour of the various formulations were 
checked and it was found that % buoyancy of the 
microspheres ranged from 0% to 44% with F-17 showing no 
buoyancy at all and F-9 showing highest % buoyancy. Results 
of this test are depicted in Table 5. 
Table 5: In-vitro % buoyancy of formulations 
 
 
 
Fig 6: In-vitro % buoyancy of formulations 
FTIR Spectrophotometric Analysis- 
 
Fig 7: FTIR Spectra of DS + EC 
 
Fig 8: FTIR Spectra of EC 
Formulation Buoyancy % Formulation Buoyancy %
F-1 21 F-10 12.5
F-2 19.67 F-11 6.83
F-3 22.66 F-12 12.83
F-4 38.5 F-13 9
F-5 27.17 F-14 11.33
F-6 17.83 F-15 7.83
F-7 35.33 F-16 22.83
F-8 22.17 F-17 0
F-9 44
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Fig 9: FTIR Spectra of DS + Na-CMC 
 
Fig 10: FTIR Spectra of F-12 
 
Fig11: FTIR Spectra of F-17 
These recorded IR spectra were compared and analysed for 
their fingerprint region peaks and it was concluded that no 
major interactions took place between the drug and 
excipients with only minor changes in the peaks of 
functional groups. 
Surface morphology- 
The external surface morphology of two formulations of 
microspheres (F-15 and F-21) were studied using SEM. The 
surface of the microspheres can be observed to be rough due 
to the incorporation of higher concentration of drug during 
formulation. The roughness of the surface of the 
microspheres is also due to the use of CaSO4 hemihydrate as 
a hardening agent during the formulation process. It can be 
inferred from the SEM images that the formulated 
microspheres were not porous and didn’t contain any gaps 
on the surface. 
 
 
Fig 12: SEM photographs of DS-loaded microspheres (F-17) 
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Fig 13: SEM photographs of DS-loaded microspheres (F-11) 
 
In-vitro biodegradability studies- The prepared 
microspheres were subjected to biodegradation studies in-
vitro using PBS as the medium over a period of 15 days 
during which the microspheres showed a constant decrease 
in weight which indicates that the microspheres gradually 
degraded over-time releasing the drug in an extended 
manner. The results of in-vitro biodegradability studies are 
shown in Table 6. 
 
Table 6: In-vitro biodegradation pattern of formulated microspheres 
 
 
Fig 14: In-vitro biodegradation pattern of F-1 to F-6 
Formulation Day 0 (500mg) Day 3 (mg) Day 6 (mg) Day 9 (mg) Day 12 (mg) Day 15 (mg)
F-1 500 384 252 143 35 0
F-2 500 407 284 168 62 18
F-3 500 412 334 210 106 33
F-4 500 416 328 216 93 16
F-5 500 424 320 206 124 52
F-6 500 436 359 242 158 36
F-7 500 438 354 259 142 23
F-8 500 445 367 275 188 45
F-9 500 431 375 263 167 30
F-10 500 457 388 293 175 68
F-11 500 438 363 287 172 56
F-12 500 455 391 306 192 81
F-13 500 415 338 263 184 86
F-14 500 436 371 286 189 57
F-15 500 442 375 298 215 129
F-16 500 381 278 174 82 16
F-17 500 405 291 184 117 42
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Fig 15: In-vitro biodegradation pattern of F-7 to F-12 
 
Fig 16: In-vitro biodegradation pattern of F-13 to F-17 
In-vitro drug release studies- 
The in-vitro drug release patterns of the various 
formulations are shown in figures. F-9 (12.5% CaSO4) 
showed a prolonged release of drug for 11 days. At the end 
of day 5, microspheres of F-9 showed a drug release of 
nearly 65%. F-14 microspheres (containing 75% CaSO4) 
released the drug at the fastest rate i.e. within 4 days. From 
the study of drug release pattern from the various 
formulations, it can be noted that the formulations 
incorporated with CaSO4 tend to release drug for longer. The 
potential reason for this could be the hardening of the 
surface of the microspheres due to CaSO4 which retards the 
release of the drug. However, higher concentration of CaSO4 
used for the preparation of microspheres allows lesser 
amount of drug to be encapsulated which is released within 
a few days. 
 
 
Fig 17: In-vitro drug release pattern of formulation F-1 to F-6 
0
50
100
150
200
250
300
350
400
450
500
F-7 F-8 F-9 F-10 F-11 F-12
W
ei
gh
t 
in
 m
g 
Day 0 (500mg) Day 3 (mg) Day 6 (mg) Day 9 (mg) Day 12 (mg) Day 15 (mg)
0
50
100
150
200
250
300
350
400
450
500
F-13 F-14 F-15 F-16 F-17
W
ei
gh
t 
in
 m
g 
Day 0 (500mg) Day 3 (mg) Day 6 (mg) Day 9 (mg) Day 12 (mg) Day 15 (mg)
0
20
40
60
80
100
0 25 50 75 100 125 150 175 200
%
 c
u
m
u
la
ti
ve
 d
ru
g 
re
le
as
e
 
Time (hours) 
F-1 to F-6 
F-1 F-2 F-3 F-4 F-5 F-6
Soundrapandian et al                                                                                     Journal of Drug Delivery & Therapeutics. 2019; 9(3-s):430-442 
ISSN: 2250-1177                                                                                   [441]                                                                                     CODEN (USA): JDDTAO 
 
Fig 18: In-vitro drug release pattern of F-7 to F-12 
 
Fig 19: In-vitro drug release pattern of F-13 to F-17 
 
Kinetic modelling of drug release- 
Based on the tests performed on the different formulations 
of microspheres, F-9 was selected for kinetic modelling for 
drug release as it displayed satisfactory properties for all the 
tests as well as provided drug release the longest. 
 
Fig 7: Kinetic modelling of drug release 
Formulation Zero-order 
(r2) 
First-order 
(r2) 
Higuchi 
(r2) 
Korsmeryer-Peppas 
r2 n 
F-9 0.9085 0.9932 0.9961 0.8978 0.677 
 
After fitting the drug release values to the various models, r2 
values of the zero-order and first-order model indicated that 
F-9 followed first-order drug release pattern. The highest 
regression (0.9961) was obtained for Higuchi model. 
Korsmeyer-peppas model was used to explain the 
mechanism of drug release. The value of slope (n) was 
calculated and found to be 0.677 which indicated that the 
drug release from the formulation was by non-fickian 
anomalous transport i.e. coupling of diffusion and erosion, 
which indicates that the drug release is sustained by more 
than one process. 
CONCLUSION 
The present study represents the first step in the 
development of Diclofenac sodium-loaded microspheres 
dedicated to intra-articular drug delivery. DS-loaded Ethyl 
cellulose and Sodium Carboxymethyl cellulose microspheres 
were successfully prepared by using thermal control and 
ionotropic cross-linking methods. From compatibility 
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studies by FTIR, it was confirmed that no chemical change 
occurred in the entrapped drug. It was also noted that for 
hardening of the microspheres, the higher concentration of 
CaSO4 used resulted in lower amount of drug being 
encapsulated. Concentration of CaSO4 also influenced drug 
release; formulations prepared using lower concentrations 
of the hardening agent (12.5%, 25%) provided drug release 
for longer than the formulations with higher concentrations 
(50%, 75%) and the formulations containing no hardening 
agent. After analysing the reports from the various tests 
carried out, it can be concluded that F-7, F-8 and F-9 show 
the most acceptable and satisfactory properties among 
which F-9 provides prolonged release the longest i.e. up to 
11 days. 
The prepared microspheres prolong the release of 
Diclofenac sodium which is potentially reproducible in other 
drugs (intended for pain and inflammation management in 
the bone joint) which exhibit rapid release rates. 
REFERENCES 
1. Kidd BL, Langford RM, Wodehouse T. Arthritis and pain. 
Current approaches in the treatment of arthritic pain. 
Arthritis research & therapy. 2007 Jun; 9(3):214. 
2. Conaghan PG, Cook AD, Hamilton JA, Tak PP. Therapeutic 
options for targeting inflammatory osteoarthritis pain. Nature 
Reviews Rheumatology. 2019 May 8:1. 
3. Walsh DA, McWilliams DF. Mechanisms, impact and 
management of pain in rheumatoid arthritis. Nature Reviews 
Rheumatology. 2014 Oct; 10(10):581. 
4. Frank RG, Kashani JH, Parker JC, Beck NC, Brownlee-Duffeck 
MA, Elliott TR, Haut AE, Atwood CA, Smith EL, Kay DR. 
Antidepressant analgesia in rheumatoid arthritis. j 
Rheumatol. 1988 Nov 1; 15(11):1632-8. 
5. Meng Z, Huang R. Topical treatment of degenerative knee 
osteoarthritis. The American journal of the medical sciences. 
2018 Jan 1; 355(1):6-12. 
6. Bisicchia S, Tudisco C. Hyaluronic acid vs corticosteroids in 
symptomatic knee osteoarthritis: a mini-review of the 
literature. Clinical Cases in Mineral and Bone Metabolism. 
2017 May; 14(2):182. 
7. van Laar M, Pergolizzi Jr JV, Mellinghoff HU, Merchante IM, 
Nalamachu S, O'Brien J, Perrot S, Raffa RB. Pain treatment in 
arthritis-related pain: beyond NSAIDs. The open 
rheumatology journal. 2012; 6:320. 
8. Larsen C, Østergaard J, Larsen SW, Jensen H, Jacobsen S, 
Lindegaard C, Andersen PH. Intra‐articular depot formulation 
principles: Role in the management of postoperative pain and 
arthritic disorders. Journal of pharmaceutical sciences. 2008 
Nov 1; 97(11):4622-54. 
9. Evans CH, Kraus VB, Setton LA. Progress in intra-articular 
therapy. Nature Reviews Rheumatology. 2014 Jan; 10(1):11. 
10.  Elmowafy M, Elrehaily A, Elharby A, Ali T, Elelian A, 
Elsemaihy A, Elgabry N. Transdermal Drug Delivery Systems; 
Review Article. 
11.  Buchholz HW, Elson RA, Engelbrecht E, Lodenkamper H, 
Rottger J, Siegel A. Management of deep infection of total hip 
replacement. The Journal of bone and joint surgery. British 
volume. 1981 Aug; 63(3):342-53. 
12.  Lyles KW, Siris ES, Singer FR, Meunier PJ. A clinical approach 
to diagnosis and management of Paget's disease of bone. 
Journal of Bone and Mineral Research. 2001 Aug; 16(8):1379-
87. 
13.  Kim KK, Pack DW. Microspheres for drug delivery In 
BioMEMS and biomedical nanotechnology 2006 (pp. 19-50). 
Springer, Boston, MA. 
14.  Shahzad MK, Ubaid M, Raza M, Murtaza G. The formulation of 
flurbiprofen loaded microspheres using 
hydroxypropylmethycellulose and ethylcellulose. Advances in 
clinical and experimental medicine: official organ Wroclaw 
Medical University. 2013; 22(2):177-83. 
15.  Kondolot Solak E, Er A. pH-sensitive interpenetrating 
polymer network microspheres of poly (vinyl alcohol) and 
carboxymethyl cellulose for controlled release of the 
nonsteroidal anti-inflammatory drug ketorolac tromethamine. 
Artificial cells, nanomedicine, and biotechnology. 2016 Apr 2; 
44(3):817-24. 
16.  Kulkarni S, Sharma SB, Agrawal A. PREFORMULATION-A 
FOUNDATION FOR FORMULATION DEVELOPMENT. 
International Journal of Pharmaceutical, Chemical & Biological 
Sciences. 2015 Apr 1; 5(2). 
17.  Larsson J. Methods for measurement of solubility and 
dissolution rate of sparingly soluble drugs. 
18.  
http://www.chem.ucalgary.ca/courses/351/laboratory/melti
ngpoint.pdf (accessed on 17th May, 2019) 
19. https://www.flinnsci.com/api/library/Download/46b1e79b
05414c7f8e4164d9df5215ff (accessed on 17th May, 2019) 
20.  Cummings NA, Nordby GL. Measurement of synovial fluid pH 
in normal and arthritic knees. Arthritis & Rheumatism: Official 
Journal of the American College of Rheumatology. 1966 
Feb;9(1):47-56. 
21.  Goldie I, Nachemson A. Synovial pH in Rheumatoid Knee-
Joints I. The Effect of Synovectomy. Acta orthopaedica 
Scandinavica. 1969 Jan 1;40(5):634-41. 
22.  Jalsenjak I, Nicolaidou CF, Nixon JR. The in vitro dissolution of 
phenobarbitone sodium from ethyl cellulose microcapsules. 
Journal of Pharmacy and Pharmacology. 1976 Dec; 
28(12):912-4. 
23.  Das MK, Senapati PC. Evaluation of furosemide-loaded 
alginate microspheres prepared by ionotropic external 
gelation technique. Acta Pol Pharm. 2007; 64(3):253-62. 
24.  Gangurde HH, Chavan NV, Mundada AS, Derle DV, 
Tamizharasi S. Biodegradable chitosan-based ambroxol 
hydrochloride microspheres: Effect of cross-linking agents. 
Journal of Young Pharmacists. 2011 Jan 1; 3(1):9-14. 
25.  Trivedi P, Verma AM, Garud N. Preparation and 
characterization of aceclofenac microspheres. Asian Journal of 
Pharmaceutics (AJP): Free full text articles from Asian J 
Pharm. 2014; 2(2). 
26.  https://www.sigmaaldrich.com/technical-
documents/articles/materials-science/drug-delivery/drug-
delivery-questions.html 
27.  Pandey N, Sah AN, Mahara K. Formulation and evaluation of 
floating microspheres of nateglinide. International Journal of 
Pharma Sciences aand Research. 2016; 7(11):453-64. 
28.  Pi C, Yuan J, Liu H, Zuo Y, Feng T, Zhan C, Wu J, Ye Y, Zhao L, 
Wei Y. In vitro and in vivo evaluation of curcumin loaded 
hollow microspheres prepared with ethyl cellulose and citric 
acid. International journal of biological macromolecules. 2018 
Aug 1; 115:1046-54. 
29.  Rout PK, Nayak BS. Formulation design, preparation of 
losartan potassium microspheres by solvent evaporation 
method and it’s in vitro characterization. Archives of 
Pharmaceutical Sciences and Research. 2009; 1(1):166-70. 
30.  Jagtap YM, Bhujbal RK, Ranade AN, Ranpise NS. Effect of 
various polymers concentrations on physicochemical 
properties of floating microspheres. Indian journal of 
pharmaceutical sciences. 2012 Nov; 74(6):512. 
31.  Riley RE, Hausner HH. Effect of particle size distribution on 
the friction in a powder mass. Int. J. Powder Met. 1970;6. 
32.  https://particle.dk/methods-analytical-laboratory/bulk-and-
tapped-density/ (accessed on 19th May, 2019) 
33.  Andhariya JV, Burgess DJ. Recent advances in testing of 
microsphere drug delivery systems. Expert opinion on drug 
delivery. 2016 Apr 2; 13(4):593-608. 
34.  Ghosh S, Choudhury D, Roy T, Mamat AB, Masjuki HH, 
Pingguan-Murphy B. Tribological investigation of diamond-
like carbon coated micro-dimpled surface under bovine 
serum and osteoarthritis oriented synovial fluid. Science and 
technology of advanced materials. 2015 May 14; 
16(3):035002. 
35.  Saravanan M, Bhaskar K, Maharajan G, Pillai KS. Development 
of gelatin microspheres loaded with diclofenac sodium for 
intra-articular administration. Journal of drug targeting. 2011 
Feb 1; 19(2):96-103.
 
 
